Targeting of biliary cancer with radiolabeled chimeric monoclonal antibody CG250

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 3, 2006, Pages 263-268

  Hendrickx, Baudewijn W ^a   Punt, Cees J A ^a   Boerman, Otto C ^a   Postema, Ernst J ^a   Oosterwijk, Egbert ^a   Mavridu, Agapi ^b   Corstens, Frans H M ^a   Oyen, Wim J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Wilex Biotechnology GmbH   (Germany)

Author keywords

Biliary cancer; cG250; Radioimmunoscintigraphy; Radioiodinated antibody

Indexed keywords

CARBONATE DEHYDRATASE IX; CHIMERIC MONOCLONAL ANTIBODY CG250 I 131; CHIMERIC MONOCLONAL ANTIBODY CG250 IN 111; MONOCLONAL ANTIBODY; RADIOISOTOPE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BILE DUCT CANCER; BILE DUCT CARCINOMA; CANCER PATIENT; CANCER STAGING; CASE REPORT; CONTROLLED STUDY; DOSE RESPONSE; DRUG LIVER LEVEL; FEMALE; GALLBLADDER CARCINOMA; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INJECTION; ISOTOPE LABELING; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOIMMUNOTHERAPY; WHOLE BODY SCINTISCANNING;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BILIARY TRACT NEOPLASMS; CARBONIC ANHYDRASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; QUALITY CONTROL; RADIOIMMUNOTHERAPY; RADIONUCLIDE IMAGING; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33746345628     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.263     Document Type: Article

References (28)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10.
2. Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 1994;14:109.
3. Hamrick RE, Jr., Liner FJ, Hastings PR, et al. Primary carcinoma of the gallbladder. Ann Surg 1982;195:270.
4. Oosterwijk E, Debruyne FM, Schalken JA. The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma. Semin Oncol 1995;22:34.
5. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal-cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997;15:1529.
6. Grabmaier K, Vissers JL, De Weijert MC, et al. Molecular cloning and immunogenicity of renal-cell carcinoma-associated antigen G250. Int J Cancer 2000;85:865.
7. Kaluz S, Kaluzova M, Opavsky R, et al. Transcriptional regulation of the MN/CA 9 gene coding for the tumor-associated carbonic anhydrase IX. Identification and characterization of a proximal silencer element. J Biol Chem 1999;274:32588.
8. Saarnio J, Parkkila S, Parkkila AK, et al. Transmembrane carbonic anhydrase, MN/CAIX, is a potential biomarker for biliary tumours. J Hepatol 2001;35:643.
9. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal-cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997;15:1529.
10. Oosterwijk E, Debruyne FM. Radiolabeled monoclonal antibody G250 in renal-cell carcinoma. World J Urol 1995;13:186.
11. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal-cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997;15:1529.
12. Velders MP, Litvinov SV, Warnaar SO, et al. New chimeric antipancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res 1994;54:1753.
13. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 1986;38:489.
14. Pastorekova S, Parkkila S, Parkkila AK, et al. Carbonic anhydrase IX, MN/CAIX: Analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1997;112:398.
15. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal-cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997;15:1529.
16. Uemura H, Nakagawa Y, Yoshida K, et al. MN/CAIX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 1999;81:741.
17. Brouwers AH, Buijs WC, Oosterwijk E, et al. Targeting of metastatic renal-cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: An intrapatient comparison. Clin Cancer Res 2003;9:3953S.
18. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal-cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997;15:1529.
19. Steffens MG, Boerman OC, De Mulder PH, et al. Phase I radioimmunotherapy of metastatic renal-cell carcinoma with 1311-labeled chimeric monoclonal antibody G250. Clin Cancer Res 1999;5:3268S.
20. 186Re. J Nucl Med 2004;45:327.
21. Lindmo T, Bunn PA, Jr. Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling. Meth Enzymol 1986;121:678.
22. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal-cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997;15:1529.
23. 186Re. J Nucl Med 2004;45:327.
24. Brouwers AH, Buijs WC, Oosterwijk E, et al. Targeting of metastatic renal-cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: An intrapatient comparison. Clin Cancer Res 2003;9:3953S.
25. Brouwers AH, Buijs WC, Oosterwijk E, et al. Targeting of metastatic renal-cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)1 or (111)In: An intrapatient comparison. Clin Cancer Res 2003;9:3953S.
26. Steffens MG, Boerman OC, Oyen WJ, et al. Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal-cell carcinoma: Implications for fractionated dose radioimmunotherapy. Cancer Res 1999;59:1615.
27. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal-cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997;15:1529.
28. Saarnio J, Parkkila S, Parkkila AK, et al. Transmembrane carbonic anhydrase, MN/CAIX, is a potential biomarker for biliary tumours. J Hepatol 2001;35:643.